© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers
Anderson Explains Benefits of PARP Inhibitors in Ovarian Cancer
September 06, 2020
The case of a 49-year-old African American woman with ovarian cancer was discussed during a virtual Case Based Peer Perspective event led by Matthew L. Anderson, MD, PhD.
Moving Toward Personalized Medicine, Immunotherapy Gains Foothold in Ovarian Cancer
August 17, 2020
“What we’re trying to do is move toward more personalized precision medicine based on what actually happens inside the tumor."
FDA Fast Track Designation Granted to Novel ADC for Heavily Pretreated Platinum-Resistant Ovarian Cancer
August 11, 2020
The FDA has granted a fast track designation to a novel antibody-drug conjugate for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to 3 prior lines of systemic therapy, or for patients who previously received 4 lines of systemic therapy regardless of their platinum status.
FDA Approves HPV Test With Extended Genotyping Capabilities
July 24, 2020
The expanded version of the BD Onclarity HPV Assay received approval for a pre-market approval supplement from the FDA, making it the only assay approved right now that individually identifies and reports human papillomavirus genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, as well as the standard 16,18, and 45.
Breast, Ovarian Screening Questionnaire Reveals Just 1 in 5 Women Meet NCCN Criteria for Genetic Testing
July 21, 2020
A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.
Precision Medicine Guiding Ovarian Cancer Treatment
July 15, 2020
Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.
Berzosertib Doublet Becomes First AFT inhibitor to Show Benefit in Platinum-Resistant High-Grade Serous Ovarian Cancer
July 15, 2020
The first randomized study of an ATR inhibitor in any malignancy demonstrated the benefit of berzosertib added to gemcitabine as treatment of patients with platinum-resistant high-grade serous ovarian cancer, according to a recently published study.
WEE-1 Inhibition Identified as a Potential Treatment Strategy for Recurrent Uterine Serous Carcinoma
July 11, 2020
In an interview with Targeted Oncology, Joyce F. Liu, MD, MPH, discussed the details of the phase 2 study of adavosertib in recurrent uterine serous carcinoma and the implications of this research for clinical practices.
Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast Cancer
July 04, 2020
According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.
Randall Discusses Testing and Treatment Choices for Ovarian Cancer
July 03, 2020
Leslie M. Randall, MD, MAS, discussed the treatment regimens available for an African American patient with ovarian cancer.